A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases.

Callum Ah DochertyAnuruddika J FernandoSarah Rosli Maggie LamRoland E DolleManuel A NaviaRonald FarquharDanny La FranceMichelle D TateChristopher K MurphyAdriano G Rossi Ashley Mansell

Published in: Clinical & translational immunology (2023)

ADS032 is the first described dual inflammasome inhibitor and a potential therapeutic to treat both NLRP1- and NLRP3-associated inflammatory diseases and also constitutes a novel tool that allows examination of the role of NLRP1 in human disease.

Keyphrases

nlrp inflammasome
endothelial cells
oxidative stress
smoking cessation
replacement therapy